Demosthenes Bouros (Athens, Greece), Elisabeth Bendstrup (Vejle, Denmark), Martina Vašáková (Praha, Czech Republic), Claudia Ravaglia (Brisighella (RA), Italy)
Fibroblasts from IPF explanted lungs have mitochondrial dysfunction and short telomeres leading to an increased senescence phenotype
Mauricio Rojas (Pittsburgh, United States of America), Diana Alvarez, Nayra Cardenes, Catherine Corey, Vidya Hanumanthu, Hanna D’Cunha, Marta Bueno, John Sembrat, Mary Armanios, Ana Mora, Mauricio Rojas
|   |
Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity
Shun Morizumi (Tokushima, Japan), Shun Morizumi, Seidai Sato, Shuichi Abe, Hiroyasu Okazaki, Yanjuan Chen, Hisatsugu Goto, Yoshinori Aono, Hirohisa Ogawa, Masaki Hanibuchi, Hisanori Uehara, Yasuhiko Nishioka
| |
Anti-parietal cell autoimmunity in IPF patients
Guillaume Beltramo (Dijon, France), Guillaume Beltramo, Nicolas Peron, Pascale Nicaise, Claire Danel, Marie-Pierre Debray, Pauline Pradère, Aurélien Justet, Raphaël Borie, Marie-Christine Dombret, Camille Taillé, Michel Aubier, Bruno Crestani
| |
Thyroid hormone inhibits pulmonary fibrosis through enhancement of mitochondrial function in alveolar epithelial cells
Argyris Tzouvelekis (New Haven, United States of America), Argyris Tzouvelekis, Guoying Yu, Jose Herazo-Maya, Rong Wang, Joao Pedro S. Werneck de Castro, Giuseppe DeIuliis, Farida Ahangari, Tony Woolard, Rafael Arrojo e Drigo, Robert Homer, Anup Srivastava, Erica Herzog, Patty Lee, Antonio Bianco, Naftali Kaminski
| |
Glutathione peroxidase 3 localizes to the epithelial lining fluid and the extracellular matrix in lung fibrosis
Claudia Staab-Weijnitz (Munich, Germany), Andrea Schamberger, Herbert Schiller, Isis Fernandez, Martina Sterclova, Katharina Heinzelmann, Elisabeth Hennen, Rudolf Hatz, Jürgen Behr, Martina Vasakova, Matthias Mann, Oliver Eickelberg, Claudia Staab-Weijnitz
| |
Interferon-γ pretreated human MSC show improved efficiency in humanized mice model of pulmonary fibrosis
Ming Liu (Guangzhou, China), Ming Liu, Ke Ni, Jian Zheng
| |
Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis
Yong Chul Lee (Jeonju, Republic of Korea), Yong Chul Lee, So Ri Kim, Kyung Bae Lee, Hae Jin Park, Soon Ha Kim
| |
New therapies in IPF: The Hammersmith Hospital experience
Robina K. Coker (London, United Kingdom), Robina K. Coker, Philip W. Ind
| |
Effect of nintedanib on cough and health related quality of life in patients with idiopathic pulmonary fibrosis
M.J.G. van Manen (Rotterdam, Netherlands), Mirjam van Manen, Nelleke Tak, Henk Hoogsteden, Marlies Wijsenbeek
| |
Intolarence of pirfenidone and its associated factors in the real world
Shunsuke Teraoka (Kobe city, Japan), Shunsuke Teraoka, Daichi Fujimoto, Munehiro Ito, Yoshihiro Nakagawa, Jiro Ito, Mariko Kogo, Yuki Sato, Kato Ryoji, Kazuma Nagata, Atsushi Nakagawa, Kojiro Otsuka, Yukimasa Hatachi, Keisuke Tomii
| |
Pirfenidone in patients with advanced idiopathic pulmonary fibrosis: First experience
Filip Hoet (Leuven, Belgium), Filip Hoet, Jonas Yzerbyt, Wim A. Wuyts
| |
Onset of symptoms in idiopathic pulmonary fibrosis: A case-control study
Thomas Hewson (Nottingham, United Kingdom), Thomas Hewson, Tricia McKeever, Jack Gibson, Richard Hubbard, John Hutchinson
| |
The effect of emphysema in patients with idiopathic pulmonary fibrosis; evaluation using quantitative CT analysis
Hiroaki Nakagawa (Otsu, Shiga, Japan), Hiroaki Nakagawa, Yuichi Higami, Kentaro Fukunaga, Yasuki Uchida, Ruriko Yukimura, Wataru Shigemori, Yumiko Kashiwagi, Masafumi Yamaguchi, Taishi Nagao, Emiko Ogawa, Yasutaka Nakano
| |
Comparison of changes of the King’s brief interstitial lung disease questionnaire (K-BILD) with other health status measures
Monique Wapenaar-deKorver (Vlaardingen, Netherlands), Monique Wapenaar-deKorver, Amit S. Patel, Surinder S. Birring, Juanita A. Haagsma, Marlies S. Wijsenbeek
| |
Idiopathic pulmonary fibrosis: Gender differences in survival and functional decline. A retrospective study
Fabián Matias Caro (Buenos Aires, Argentina), Fabián Matias Caro, Martín Eduardo Fernández, María Laura Alberti, Francisco Paulin
| |
HRCT in the evaluation of functional decay in IPF
Elisabetta Balestro (Padova, Italy), Elisabetta Cocconcelli, Giulio Barbiero, Paolo Spagnolo, Graziella Turato, Roberta Polverosi, Davide Biondini, Alessia Fraccaro, Piera Peditto, Manuel G. Cosio, Marina Saetta, Elisabetta Balestro
| |
The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF)
Marlies S. Wijsenbeek (Rotterdam, Netherlands), Marlies S. Wijsenbeek-Lourens, Merel L. Kimman, Adrienne Rotteveel, Xana van Jaarsveld, Stephanie S. Weinreich, Remy Mostard, Carmen D. Dirksen
| |
Does early diagnosis of idiopathic pulmonary fibrosis matter? Real- world´s data from the EMPIRE registry
Martina Vašáková (Praha, Czech Republic), Martina Vašáková, Martina Sterclova, Jan Kus, Vladimir Bartos, Marta Hajkova, Martina Doubkova, Veronika Muller, Martina Plackova, Monika Zurkova, Vladimira Lostakova, Ladislav Lacina, Vladimir Rihak, Frantisek Petrik, Pavlina Lisá, Radka Bittenglova, Dragana Jovanovic, Richard Tyl, Gustav Ondrejka, Hana Suldova, Jaroslav Lnenicka, Jana Psikalova, Tomas Snizek, Jiri Homolka, Renata Kralova, Jan Kervitzer, Michal Svoboda, Jana Strenkova
| |
Do typical and atypical HRCT patterns make difference in prognosis of patients with IPF?
Martina Vašáková (Praha, Czech Republic), Martina Vašáková, Martina Sterclova, Vladimir Bartos, Martina Doubkova, Martina Plackova, Monika Zurkova, Vladimira Lostakova, Ladislav Lacina, Vladimir Rihak, Frantisek Petrik, Pavlina Lisa, Radka Bittenglova, Richard Tyl, Gustav Ondrejka, Hana Suldova, Jaroslav Lnenicka, Jana Psikalova, Tomas Snizek, Jiri Homolka, Renata Kralova, Jan Kervitzer, Michal Svoboda, Jana Strenkova, Athol Wells
| |